Pharma’s “patent squeeze” isn’t just about patents—it’s about time.
For years, the public conversation has focused on the headline battles: blockbuster drugs, court filings, and the moment a patent finally expires. But the real contest often happens …

Patients aren’t asking “about patents.” They’re asking: “Will I be able to keep taking my medicine?”
If you’ve spent any time reading patient forums, search queries, or comment sections, you’ll notice a pattern: people rarely talk about “drug switching…

Evergreen the brand—or beat it. That’s the strategic fork in the road for any company trying to enter a drug market where “brand” doesn’t just mean a product. It means a patent portfolio designed to delay competition.
In pharma, the most expensive surp…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The generic drug industry has always been a game of speed and certainty—figuring out what’s protected, what’s not, and what can be made next. But for years…

Patent cliffs don’t just “happen.” They’re engineered—by timing, leverage, and payer behavior.
For pharma leaders, the phrase “beat the patent cliff” can sound like a slogan. But in practice, it’s a campaign discipline: anticipating when exclusivity …

OpenAI’s GPT just did something that should make every drug-patent strategist sit up: it reportedly “smashed” through some of the most stubborn cliffs in pharma IP—by accelerating how companies find, interpret, and act on patent landscapes. The headlin…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—filed on a calendar you didn’t know you were watching.
Paragr…

Your drug’s “patent life” isn’t one number—it’s a moving target across the GCC. Here’s how to know what you’re really protecting.
If you’re a pharma leader, counsel, or BD executive, you’ve probably heard the same comforting phrase: “Our patent runs fo…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “improving” the drug. They’re extending its life. Here are 4 signals to watch.
In pharma, time is the real battleground.
A competitor doesn’t always need to invent a new molecule to win the next chapter. Often, they simply keep th…